[The safety of new quinolone treatment--levoflaxacin (tavanic) and moxiflocacin (megaxin)-- in the community].
Bolkovshtein
M
M
Lederman
N
N
Berkovitch
M
M
D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001372:Aza Compounds; D024841:Fluoroquinolones; D006801:Humans; D000077266:Moxifloxacin; D015242:Ofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D011804:Quinolines; D012449:Safety
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D015242:Ofloxacin; D000077266:Moxifloxacin